Roche Diagnostics DNA-Based Clot Risk Tests Set For Early 2004 Launch
This article was originally published in The Gray Sheet
Executive Summary
Roche plans to develop additional DNA-based tests for inherited disorders using the same platform as its initial assays for genetic clotting risk, the firm says
You may also be interested in...
FDA News In Brief
Factor V Leiden: Effective April 15, FDA 1Factor V Leiden DNA mutation detection system final rule formalizes Class II (special controls) status for the genetic tests intended to aid in diagnosis of patients thought to have thrombophilia. The final rule and accompanying 2special controls guidance - among the first product-specific guidance the IVD office has issued for genetic tests - was prompted by Roche's de novo approval Dec. 17 (3"The Gray Sheet" Dec. 22, 2003, p. 26). Stand-alone Factor V tests for general or prenatal screening are outside the scope of the rule and guidance...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.